Japan’s Takeda Pharmaceuticals has reached a deal worth up to $2.2bn to develop an Alzheimer’s vaccine made by Swiss start-up AC Immune, as drug companies race to invest in potentially lucrative new treatments for the disease.
日本武田制药(Takeda Pharmaceutical)达成一项价值高达22亿美元的协议，开发由瑞士初创公司AC Immune研发的一款阿尔茨海默病(Alzheimer’s)疫苗。目前各制药公司竞相投资于针对这种病症的潜在利润丰厚的新疗法。
您已阅读9%（347字），剩余91%（3569字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。